Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 1, 2019

Primary Completion Date

June 1, 2022

Study Completion Date

September 1, 2022

Conditions
DiabetesDiabetic FootDiabetic Foot Infection
Interventions
DRUG

Phage

The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.

Trial Locations (1)

DE22 3DT

University Hospitals Derby and Burton NHS Foundation Trust, Derby

Sponsors
All Listed Sponsors
collaborator

Wellcome Trust

OTHER

collaborator

BioPhage Theraputics Limited

UNKNOWN

collaborator

Nottingham University Hospitals NHS Trust

OTHER

lead

University Hospitals of Derby and Burton NHS Foundation Trust

OTHER